Jeffrey Flier Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey Flier sold 3,053 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total value of $164,495.64. Following the sale, the director owned 27,856 shares in the company, valued at $1,500,881.28. This trade represents a 9.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 2.2%

SRRK stock opened at $56.56 on Wednesday. The stock has a market cap of $6.78 billion, a P/E ratio of -15.75 and a beta of 0.67. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The stock’s fifty day simple moving average is $48.79 and its two-hundred day simple moving average is $46.75. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $57.80.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the firm earned ($0.67) earnings per share. Analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on SRRK. HC Wainwright boosted their target price on shares of Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Tuesday, April 21st. JPMorgan Chase & Co. upped their price objective on Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. Wedbush increased their price objective on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a report on Wednesday, April 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $56.00.

Institutional Trading of Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the business. Redmile Group LLC increased its position in shares of Scholar Rock by 73.7% during the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after buying an additional 3,845,775 shares during the period. Orbis Allan Gray Ltd boosted its position in shares of Scholar Rock by 1,034.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after acquiring an additional 3,126,677 shares during the period. Wellington Management Group LLP boosted its position in shares of Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after acquiring an additional 2,521,022 shares during the period. Holocene Advisors LP purchased a new position in Scholar Rock during the third quarter valued at approximately $91,670,000. Finally, Norges Bank purchased a new position in Scholar Rock during the fourth quarter valued at approximately $91,603,000. Institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).